Corporate Website
Africa
Argentina
Asia
Australia
Belgium
Brazil
Bulgaria
Canada (EN)
Chile
China
Colombia
Denmark
Egypt
France
Germany
Greece
Hungary
Indonesia
Italia
India
Japan
Korea
Malaysia
Mexico
Middle East
Netherlands
Peru
Philippines
Poland
Portugal
Romania
Russia
South Africa
Spain
Sweden
Thailand
Tunisia
Turkey
Ukraine
United Kingdom
USA
Vietnam
Your search for "Results" return 76 results.
The Perfect Pair is now available >
A great innovation in the protection against Newcastle and Gumboro Diseases
Mid-year results : Innovation drives Ceva’s growth >
Double-digit growth confirms long term upward trend
Ceva sponsors 8th International Symposium on Avian Influenza >
Innovation in poultry vaccines and solutions reaches beyond animal health
New commercial licenses for viral vaccine production >
Ceva takes commercial license for ProBioGen’s AGE1.CR® Cell Line for viral vaccine production
Ceva continues rapid growth in 2011 >
Twin pillar strategy of combining internal and external growth opportunities drives further global expansion
Second joint Human and Veterinary Cardiology Symposium >
Together for health, in the heart of Bordeaux
Ceva acquires Vetech Laboratories, Inc. >
Move adds significant poultry vaccine to innovative portfolio
Parasiticides >
75% of all emerging human infectious diseases are of animal origin. Thanks to its products, Ceva fight against the spread of infectious disease that can be transmitted from wild or domestic animals an...
Ceva finishes first decade of success with strong growth >
2010 results demonstrate global ability to generate sales and earnings
Ceva launches latest of its Vector Vaccines at VIV Asia 2011 >
VECTORMUNE HVT- NDV® generates strong interest at symposium organised to present new strategies to combat Newcastle Disease.